In 2022, we developed and validated the HER2DX genomic test,20 a single 27-gene expression and clinical feature-based classifier able to provide 2 independent scores to predict both long-term prognosis and likelihood of pCR in HER2-positive early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.